Cancer-Leading Proteases: Structures, Functions, and Inhibition

506 Pages·2020·7.514 MB·English

by  Dr. Satya Prakash Gupta (editor)

Cancer-Leading Proteases
Cancer-Leading
Proteases
Structures, Functions, and Inhibition
Edited by
Satya P. Gupta
Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
© 2020 Elsevier Inc. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means,
electronic or mechanical, including photocopying, recording, or any information storage
and retrieval system, without permission in writing from the publisher. Details on how to
seek permission, further information about the Publisher’s permissions policies and our
arrangements with organizations such as the Copyright Clearance Center and the Copyright
Licensing Agency, can be found at our website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by the
Publisher (other than as may be noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and
experience broaden our understanding, changes in research methods, professional practices, or
medical treatment may become necessary.
Practitioners and researchers must always rely on their own experience and knowledge in
evaluating and using any information, methods, compounds, or experiments described herein.
In using such information or methods they should be mindful of their own safety and the safety
of others, including parties for whom they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors,
assume any liability for any injury and/or damage to persons or property as a matter of products
liability, negligence or otherwise, or from any use or operation of any methods, products,
instructions, or ideas contained in the material herein.
Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
ISBN 978-0-12-818168-3
For information on all Academic Press publications
visit our website at https://www.elsevier.com/books-and-journals
Publisher: Andre Gerhard Wolff
Acquisition Editor: Erin Hill-Parks
Editorial Project Manager: Tracy Tufaga
Production Project Manager: Kiruthika Govindaraju
Cover Designer: Victoria Pearson
Typeset by SPi Global, India
Contributors
Numbers in parentheses indicate the pages on which the authors’ contributions begin.
Nilanjan Adhikari (265), Natural Science Laboratory, Division of Medicinal and
Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur
University, Kolkata, India
Gouri Ahir (295), RASA Life science Informatics, Pune, India
Hanan A. Al-Dossary (417), Institute for Research and Medical Consultations (IRMC),
Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
Meneerah Abdurhman Aljafary (417), Department of Biology, College of Science,
Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
Khulood Mohammed Al-Khater (417), Department of Anatomy, College of Medicine,
Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
Ebtesam Abdullah Al-Suhaimi (417), Department of Biology, College of Science,
Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
Sk. Abdul Amin (265), Natural Science Laboratory, Division of Medicinal and
Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur
University, Kolkata, India
Ghulam Md Ashraf (295), King Fahd Medical Research Center; Department of
Medical Laboratory Technology, Faculty of Applied Medical Sciences, King
Abdulaziz University, Jeddah, Saudi Arabia
Reem A. Assuhaimi (417), Institute for Research and Medical Consultations (IRMC),
Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
Himani Balutia (243), National Institute of Pharmaceutical Education and Research
(NIPER), Kolkata, India
Anwar L. Bilgrami (295), Deanship of Scientific Research, King Abdulaziz University,
Jeddah, Saudi Arabia
Diana Campos-Iglesias (73), Department of Biochemistry and Molecular Biology,
University Institute of Oncology (IUOPA), University of Oviedo, Oviedo, Spain
Sapana Sameer Chaudhary (295), RASA Life science Informatics, Pune, India
Sameer Choudhary (295), RASA Life science Informatics, Pune, India
V. Cicaloni (13), Department of Biotechnology, Chemistry and Pharmacy (Department
of Excellence 2018-2022), University of Siena; Toscana Life Sciences, Siena, Italy
Rohit Dutt (51), School of Medical and Allied Sciences, GD Goenka University,
Gurugram, India
xiii
xiv Contributors
Sayan Dutta Gupta (1), Department of Pharmaceutical Chemistry, Gokaraju Rangaraju
College of Pharmacy, Hyderabad, India
Abdelhamid Elaissari (417,449), Univ Lyon, University Claude Bernard Lyon-1,
CNRS, LAGEP-UMR 5007, Lyon, France
I. Fotopoulos (165), Department of Pharmaceutical Chemistry, School of Pharmacy,
Aristotle University of Thessaloniki, Thessaloniki, Greece
José M.P. Freije (73), Department of Biochemistry and Molecular Biology, University
Institute of Oncology (IUOPA), University of Oviedo, Oviedo, Spain
Ankit Ganeshpurkar (121), Pharmaceutical Chemistry Research Laboratory,
Department of Pharmaceutical Engineering & Technology, Indian Institute of
Technology (Banaras Hindu University), Varanasi, India
Vandana Garg (51), MD University, Rohtak, India
Rishitha Gundala (243), National Institute of Pharmaceutical Education and Research
(NIPER), Kolkata, India
Satya P. Gupta (1), Department of Pharmaceutical Technology, Meerut Institute of
Engineering and Technology, Meerut, India
Nahor Haddish-Berhane (359), Janssen Research & Development, LLC, Spring
House, PA, United States
D. Hadjipavlou-Litina (165), Department of Pharmaceutical Chemistry, School of
Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece
B.S. Harish (215), Bioprospecting Laboratory, Department of Biotechnology, School
of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, India
Srabanti Jana (121), Pharmaceutical Chemistry Research Laboratory, Department of
Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras
Hindu University), Varanasi, India
Tarun Jha (265), Natural Science Laboratory, Division of Medicinal and Pharmaceutical
Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata,
India
Deepak Kumar (391), Organic & Medicinal Chemistry, Council of Scientific and
Industrial Research-Indian Institute of Chemical Biology, Kolkata, India
Devendra Kumar (121), Pharmaceutical Chemistry Research Laboratory, Department
of Pharmaceutical Engineering & Technology, Indian Institute of Technology
(Banaras Hindu University), Varanasi, India
Sanjay Kumar (391), Division of Biology, Indian Institute of Science Education &
Research Tirupati, Tirupati, India
R. Lavanya (243), National Institute of Pharmaceutical Education and Research
(NIPER), Kolkata, India
Carlos López-Otín (73), Department of Biochemistry and Molecular Biology,
University Institute of Oncology (IUOPA), University of Oviedo, Oviedo, Spain
A.K. Madan (51), Pt. BD Sharma University of Health Sciences, Rohtak, India
Ayesha Mahmood (449), Faculty of Pharmacy, The University of Lahore, Lahore,
Pakistan
Contributors xv
Subhajit Makar (121), Pharmaceutical Chemistry Research Laboratory, Department of
Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras
Hindu University), Varanasi, India
Tanima Mandal (391), Cancer Biology & Inflammatory Disorder Division, Council
of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata,
India
Ashima Nagpal (51), School of Medical and Allied Sciences, GD Goenka University,
Gurugram, India
Dolly A. Parasrampuria (359), Janssen Research & Development, LLC, Spring House,
PA, United States
A. Peperidou (165), Department of Pharmaceutical Chemistry, School of Pharmacy,
Aristotle University of Thessaloniki, Thessaloniki, Greece
F. Pettini (13), Department of Biotechnology, Chemistry and Pharmacy (Department of
Excellence 2018-2022), University of Siena, Siena, Italy
Nitesh Kumar Poddar (183), Department of Biosciences, Manipal University Jaipur,
Jaipur, Rajasthan, India
E. Pontiki (165), Department of Pharmaceutical Chemistry, School of Pharmacy,
Aristotle University of Thessaloniki, Thessaloniki, Greece
Pankaj Kumar Rai (183), Department of Biotechnology, Invertis University, Bareilly,
India
Vijaya Ravinayagam (417), Nanomedicine Research Department, Institute for
Research and Medical Consultations (IRMC), Deanship of Scientific Research,
Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
Sakshi Rawat (295), RASA Life science Informatics, Pune, India
Kuldeep K. Roy (243), National Institute of Pharmaceutical Education and Research
(NIPER), Kolkata, India
Priyanka Saha (391), Cancer Biology & Inflammatory Disorder Division, Council of
Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata,
India
Adeeb Shehzad (417), Department of Clinical Pharmacy, Institute for Research
and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University,
Dammam, Saudi Arabia
Devendra Shukla (391), Cancer Biology & Inflammatory Disorder Division, Council
of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata,
India
Sushil Kumar Singh (121), Pharmaceutical Chemistry Research Laboratory,
Department of Pharmaceutical Engineering & Technology, Indian Institute of
Technology (Banaras Hindu University), Varanasi, India
O. Spiga (13), Department of Biotechnology, Chemistry and Pharmacy (Department of
Excellence 2018-2022), University of Siena, Siena, Italy
Amit Kumar Srivastava (391), Cancer Biology & Inflammatory Disorder Division,
Council of Scientific and Industrial Research-Indian Institute of Chemical Biology,
Kolkata, India
xvi Contributors
Mohamad Tarhini (417,449), Univ Lyon, University Claude Bernard Lyon-1, CNRS,
LAGEP-UMR 5007, Lyon, France
Rajiv Kumar Tonk (327), Department of Pharmaceutical Chemistry, Delhi
Pharmaceutical Sciences and Research University, New Delhi, India
A. Trezza (13), Department of Biotechnology, Chemistry and Pharmacy (Department
of Excellence 2018-2022), University of Siena, Siena, Italy
Kiran Babu Uppuluri (215), Bioprospecting Laboratory, Department of Biotechnology,
School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur,
India
Ravichandiran Velayutham (243), National Institute of Pharmaceutical Education and
Research (NIPER), Kolkata, India
Saroj Verma (327), Department of Pharmaceutical Chemistry, Delhi Pharmaceutical
Sciences and Research University, New Delhi, India
Alex Yu (359), Janssen Research & Development, LLC, Spring House, PA, United
States
Nadiah Zafar (449), Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan
About the Editor
Satya P. Gupta is presently a Professor
Emeritus at Meerut Institute of Engineering
and Technology (MIET), Meerut, India,
after retiring as Professor in the Department
of Applied Sciences at National Institute of
Technical Teachers’ Training and Research
(NITTTR), Bhopal. Earlier he served at Tata
Institute of Fundamental Research (TIFR),
Mumbai, a world renowned Institution of
India, Birla Institute of Technology and
Science (BITS), Pilani, and then at MIET
as its Director-cum Distinguished Professor
in the Department of Pharmacy. Professor
Gupta has a very long standing of teaching
various courses such as Physical Chemistry, Quantum Chemistry, Pharmaceutical
Chemistry, Biophysics, and Drug Design. He had obtained his M.Sc. and
D.Phil. degrees from University of Allahabad, Allahabad, in 1967 and 1971,
respectively. He is a world renowned scientist. For his work in Drug Design,
he has bagged several honors and awards. To his credit, Gupta has more than
200 research publications in highly reputed national and international journals
and several reviews in highly prestigious periodicals such as Chemical Reviews
(American Chemical Society), Progress in Drug Research (Birkhäuser Verlag,
Basel, Switzerland), and Current Medicinal Chemistry (Bentham Science, the
Netherlands), and has been on editorial board of several international journals.
Dr. Gupta himself has been editor of several scientific journals and books of
international repute published by Springer-Verlag, Berlin; Heidelberg, Germany;
CRC Press, Taylor and Francis Group; Nova Science Publishers, NY, USA; and
Elsevier (Academic Press), USA. He has delivered several invited plenary/key-
note lectures in various national and international conferences on Drug Design
as well as chaired various scientific sessions in these conferences. His scientific
activity has brought him on the forefront of scientific community of the world.
xvii
Preface
Proteases that are also known as proteinases or peptidases regulate diverse bio-
chemical processes in humans, such as gene expression, differentiation, and
cell death. A few of them are selectively found in cancer cells. The set of prote-
ases involved in cancer progression is collectively known as the “cancer degra-
dome.” There are five classes of proteases: cysteine proteases, serine proteases,
aspartic proteases, threonine proteases, and metalloproteases, all of which are
involved in cancer initiation, growth, metastasis, and invasion. This book pres-
ents a detailed account of the structures and functions of these proteases and
the mechanism by which they can be involved in cancer progression and how
they can be inhibited. Some introductory remarks on all these aspects of pro-
teases are presented by Gupta and Duttagupta in the very first chapter entitled
“Cancer-Leading Proteases: An Introduction” to arouse the curiosity among the
readers to go through the whole book. These proteases, as obvious, constitute
good targets to develop anticancer drugs. Chapter 2, written by Trezza et al. and
entitled as “Potential Roles of Protease Inhibitors as Anticancer Drugs,” focuses
attention on protease inhibitors, describing their structure and mechanism of
action. Shifting to the roles of individual families of proteases and their inhibi-
tors, Dutt et al. presented in Chapter 3 a detail of studies on cysteine proteases
and their inhibitors for anticancer drug design. In Chapter 4 entitled “Ubiquitin-
specific Proteases as Targets for Anti-cancer Drug Therapies,” Campos-Iglesias
et al. discuss the growing relevance of using ubiquitin-specific proteases (USPs)
as targets in cancer therapy and the current status of small inhibitory mole-
cules against USP functions. USPs are involved in a plethora of cellular pro-
cesses, several of which are frequently altered in cancer. Chapter 5 authored by
Ganeshpurkar et al. and entitled as “Aspartic Proteases: Potential Drug Targets
for Anticancer Drug Development” presents the structural aspects of various
aspartic proteases (APs) and a collective view on the structure and ligand-based
drug design for the inhibition of this class of proteases.
It has been found that human immunodeficiency virus (HIV) protease, one
of the enzymes crucial to the life cycle of HIV, could be important to serve as a
target to develop anticancer agents for HIV-induced cancer types. In fact, many
cancers have been found to be related to HIV infection, such as Kaposi’s sar-
coma, B-cell lymphomas (Hodgkin/Non-Hodgkin Lymphoma), leukemia, and
breast, prostate, and cervical cancers, which become the main cause of death in
HIV-infected persons. Therefore, Pontiki et al. presented in Chapter 6 entitled
xix